Eli Lilly has partnered with Dicerna to use the latter’s GalXC™ platform to discover and develop RNA interference therapies for more than 10 targets in a deal potentially worth over US$3.7 B. In addition, the companies will collaborate to develop a new nucleic acid platform. Just five days earlier, Dicerna signed an agreement with Alexion Pharmaceuticals worth up to US$637M to develop RNAi therapies for complement-mediated diseases to accompany Alexion’s Soliris® (eculizumab) and Ultomiris™.